Metabolic Profiling of CSF in Schizophrenia
Author Information
Author(s): Elaine Holmes, Tsz M Tsang, Jeffrey T.-J Huang, F. Markus Leweke, Dagmar Koethe, Christoph W Gerth, Brit M Nolden, Sonja Gross, Daniela Schreiber, Jeremy K Nicholson, Sabine Bahn
Primary Institution: Imperial College, London, United Kingdom
Hypothesis
Can metabolic profiling of cerebrospinal fluid (CSF) identify biomarkers for schizophrenia and assess the impact of early intervention on disease progression?
Conclusion
The study found that metabolic profiling of CSF shows significant differences between healthy individuals and patients with first-onset schizophrenia, and early treatment can normalize these profiles in some patients.
Supporting Evidence
- Metabolic profiles showed a significant separation between drug-naïve patients with schizophrenia and healthy controls.
- Short-term treatment with atypical antipsychotic medication normalized the CSF profiles in about 50% of patients.
- Patients treated during their first psychotic episode had a higher chance of normalizing their CSF profiles.
Takeaway
Scientists studied the fluid around the brain to find clues about schizophrenia, and they discovered that treating patients early can help fix some of the problems.
Methodology
1H nuclear magnetic resonance spectroscopy and computerized pattern recognition analysis were used to analyze CSF samples from patients and healthy controls.
Potential Biases
Potential bias due to the small number of patients treated with typical antipsychotic medications.
Limitations
The sample size was relatively small, and the study primarily focused on drug-naïve patients.
Participant Demographics
The study included 82 patients with schizophrenia and 70 healthy controls, with a focus on drug-naïve individuals.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website